Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...

Ooops... Something went wrong while loading this page.

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day. This change lagged the S&P 500's daily loss of 0.13%. On the other hand, ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Overview: Strong knowledge of data structures and recognizing common patterns makes complex coding questions easier and faster to solve.Thinking out loud during ...

Recursion Pharmaceuticals lagged the market last year. The stock doesn't have significant catalysts on the horizon. The biotech's long-term prospects also look uncertain. It might take a while for ...

Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...